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Lenvatinib for use in combination with everolimus for the treatment of patients with 
advanced renal cell carcinoma following one prior anti-angiogenic therapy. 
Summary 
In patients with metastatic renal cell cancer options for second line therapies, following 
progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical 
trials have been limited. Recently a number of agents have demonstrated efficacy in this 
setting. Here in we profile one such therapy, the combination of lenvatinib and everolimus, 
and discuss the expanded options for therapy available in this setting. 
 (1)  Introduction 
Renal cell cancer (RCC) accounts for 2-3% of all cancer diagnosed worldwide annually. In 
Europe alone there are over 84,000 new RCC diagnoses per year and RCC accounts for over 
34,000 cancer related deaths per year. [1] 
The pathogenesis of clear cell RCC, which accounts for approximately 80% of RCC, is 
characterised by inactivation of the von-Hippel-Lindau (VHL) gene on the short arm of 
chromosome 3. VHL functions as a tumor suppressor gene. The inactivation of VHL results in 
constitutive activation of the HIF (hypoxia-inducible factor) pathway. HIFs are transcription 
factors, physiologically they respond to an oxygen depleted cellular environment. HIFs 
promote angiogenesis. Activation of the HIF pathway in RCC is implicated in derangement of 
the cellular metabolism promoting anaerobic glycolysis, the pentose phosphate pathway 
and glutamine transport well above physiological levels. This in turn fuels the tumor 
microenvironment via gluconeogenesis of excess lactate. HIF, as part of its physiological role 
in wound healing, is active in promoting epithelial–mesenchymal transition.  
HIF interacts directly with multiple oncogenic pathways, such as PI3K/AKT/mTOR, but also 
indirectly acts with innumerable oncogenic pathways via genome wide epigenetic changes 
resulting in inactivation of key tumor suppressor genes. 
Epigenetic silencing of key tumor suppressor genes contributes significantly to RCC’s 
characteristic phenotype of immune evasion.  
Inactivation of VHL is thus recognised as a pivotal early step in tumorigenesis of RCC. [2] 
Significant strides forward have been made in the last decade in identifying agents that are 
active in targeting the molecular abnormalities that underlie RCC development. That said 
the sheer diversity that exists in terms of molecular aberrations in RCC predisposes to the 
development of resistance mechanisms. This is evident in clinical practice with patients 
ultimately progressing on multiple lines of targeted therapy, there is as such no cure for 
metastatic RCC (mRCC). An unmet need exists in identifying tolerable agents that result in 
improvements in overall survival (OS)and ultimately in finding a cure for RCC.  
A number of drugs have recently been approved for treatment of patients who have 
progressed on prior anti-angiogenic therapy including nivolumab, cabozantinib and the 
combination of everolimus and lenvatinib.  
(2) Overview of the market 
Prior to the development of the targeted therapies the mainstay of treatment for mRCC was 
interleukin 2 (IL-2). Interleukin 2’s use was based on observations that it induced durable 
remissions in a small number of patients (10%) but at the cost of significant toxicity. 
Targeted therapies in mRCC broadly encompass (i) VEGF targeted tyrosine kinase inhibitors 
such as sunitinib, sorafenib, axitinib and pazopanib, (ii) bevacizumab a monoclonal antibody 
to VEGF and (iii)agents targeting the PI3K/AKT/mTOR pathway such as everolimus and 
temsirolimus.[3] Recent additions to the market include the tyrosine kinase inhibitor 
cabozantinib and the check point inhibiter nivolumab.  
A limited number of clinical trials define the setting in which each of these agents is used. 
Based on evidence from phase III randomised trials the European Association of urology 
(EAU) guidelines and the National Comprehensive cancer network (NCCN) guidelines 
recommend sunitinib, pazopanib or bevacizumab in combination with IFN-α be used in 
newly diagnosed metastatic RCC (mRCC) or advanced inoperable RCC. Temsirolimus is also 
an option for patients who fulfil the criteria for ‘poor risk’ as defined by the Memorial Sloan-
Kettering Cancer Center (MSKCC) risk stratification.  
The EAU guidelines and NCCN guidelines were recently updated to recognise cabozantinib 
and nivolumab as the new standard of care in patients who have failed VEGF targeted 
therapy based on two recent pivotal phase III trials.  Everolimus or axitinib were previously 
recommended in this setting and continue to be used in clinical practice pending regulatory 
approval of newer agents. [4] 
In the third line setting, in the absence of clinical trial options, everolimus is recommended 
following VEGF targeted therapy and sorafenib is recommended following mTOR targeted 
therapy. [3] 
(2)A First Line systemic treatment 
Sunitinib, pazopanib, temsirolimus and bevacizumab in combination with IFN-α have all 
demonstrated activity in the first line setting in Phase III randomised trials.  
Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor. In a 
randomised phase III trial of 750 patients with treatment naïve mRCC sunitinib 
demonstrated improved median PFS compared to IFN-α, 11 months verses 5 months 
respectively (HR 0.42, 95% CI, 0.32 to 0.54; P<0.001). [5]At final analysis sunitinib 
demonstrated a numerically superior OS of 26.4 months compared to 21.8 months in the 
INF- α arm but did not reach statistical significance (HR 0.821; 95% CI, 0.673 to 1.001; P = 
.051). The failure of sunitinib to demonstrate a statistically significant improvement in 
overall OS may have been confounded by patient crossover to sunitinib at progression. [6] 
Pazopanib is a tyrosine kinase inhibitor with targets including VEGFR, PDGFR and KIT. In a 
phase III, randomised, double blinded, placebo controlled trial, pazopanib demonstrated 
improved median PFS compared to placebo 9.2 months versus 4.2 months respectively (HR 
0.46; 95% CI, 0.34 to 0.62; P < .0001). [7]The 435 patients consisted of 233 patients who 
were treatment naive and 202 patients who had progressed on cytokine therapy. At final 
analysis pazopanib was associated with an OS of 22.9 months and placebo with an OS of 
20.5 months. This was not statistically significant (HR 0.91; 95% CI, 0.71-1.16; P= 0.224) but 
may have been confounded by the significant rate of crossover from placebo to 
pazopanib.[8] 
In the COMPARZ trial, a phase III trial, pazopanib was shown to be non-inferior to sunitinib 
in terms of PFS in the first line setting, 8.4 months versus 9.5 months (HR 1.05; 95% CI 0.90 
to 1.22) respectively. At final analysis OS was comparable between the arms 28.3 months 
for pazopanib and 29.1 months for Sunitinib (HR 0.92; 95% CI 0.79 to 1.06; P=0.24). Toxicity 
profiles and quality of life appeared to favour pazopanib. [9]Assessments of quality of life 
and toxicity similarly favoured pazopanib in the PICSES study, a double blind cross over 
study. PICSES compared patient reports of preference, quality of life and toxicity in 114 
patients who received pazopanib followed by sunitinib or vica versa. [10] 
Bevacizumab is a monoclonal antibody to VEGF. Bevacizumab in combination with IFN- α in 
the first line setting has been examined in two Phase III trials. AVOREN randomised 649 
patients to receive either Bevacizumab in combination with IFN- α or placebo and IFN- α. 
The combination of bevacizumab and INF- α resulted in a statistically significant 
prolongation of median PFS when compared to IFN - α, 10.4 months versus 5.4 months 
respectively (HR 0.63, 95% CI 0.52-0.75; p=0.0001). At final analysis median OS was 23.3 
months for bevacizumab and IFN- α and 21.3 months for IFN- α and placebo. This difference 
in OS was not statistically significant (HR = 0.91; 95% CI, 0.76 to 1.10; P = .3360).[11] CALBG 
90206 randomised 732 patients to receive either bevacizumab and IFN- α or IFN-α 
monotherapy. Median PFS in the combination arm was 8.5 months versus 5.2 months for 
IFN-α monotherapy (HR is 0.72 (95% CI, 0.61 to 0.83; P < .0001). At final analysis the 
addition of bevacizumab to IFN-α did not result in a statistically significant prolongation in 
OS. Median overall survival in the combination arm was 18.3 months and 17.4 months in the 
IFN-α monotherapy arm (adjusted HR 0.86, 95% CI, 0.73 to 1.01; stratified log-rank P = 
.069).[12] In both AVOREN and CALBG 90206 the authors noted that receipt of further lines 
of therapy following bevacizumab may have contributed to the failure to achieve a 
statistically significant improvement in OS. 
Temsirolimus was examined in the first line setting in a phase III trial were 626 patients 
were randomised to receive single agent temsirolimus, single agent IFN-α or the 
combination of Temsirolimus and IFN-α. This trial is notable for its inclusion of patients with 
non-clear cell histology (20% of total study population) and its inclusion of patients with 
multiple negative prognostic factors. Median overall survival in the Temsirolimus arm was 
10.9 months compared to 7.3 months in the interferon arm HR 0.73 (95% CI 0.58 to 0.92; 
P=0.008). Median overall survival in the combination arm, 8.4 months, was inferior to single 
agent Temsirolimus. There was a high rate of grade 3 and grade 4 toxicity in the 
combination arm resulting in a substantial number of dose reductions and dose delays 
which may explain the inferior OS. [13] 
(2)B Second Line systemic treatment 
(2)Bi Established second line systemic treatment 
RECORD-1, a phase III trial, randomised 416 patients with mRCC who previously progressed 
on sunitinib, sorafenib or both to everolimus or placebo in a 2:1 fashion. In the total 
population median PFS in the everolimus arm was 4.6 months versus 1.9 months in the 
placebo arm (HR 0.33; P < .001). In patients who had received one previous line of VEGF 
targeted therapy median PFS was 5.4 months for everolimus and 1.9 months for placebo 
(HR, 0.32; 95%confidence interval [CI], 0.24-0.43; P<.001). In patients who had received two 
previous lines of VEGF targeted therapy median PFS in the everolimus group was 4 months 
and 1,8 months in the placebo group (HR, 0.32; 95%CI, 0.19-0.54; P<.001).[14] 
In the TARGET trial, a phase III randomised trial, 903 patients in the second line setting were 
randomised to receive either sorafenib or placebo. The majority of patients had received 
prior cytokine therapy. At progression patients in the placebo arm were allowed to cross 
over to the sorafenib arm. Median progression free survival was 5.5 months in the sorafenib 
group versus 2.8 months in the placebo group. At final analysis there was no difference in 
median OS between the two groups 17.8 months and 15.2 months for sorafenib and 
placebo respectively (HR = 0.88; P = .146). On censoring the patients on placebo who 
crossed over to sorafenib when disease progression occurred, an OS advantage was 
appreciable. In this group sorafenib was associated with a median OS of 17.8 months versus 
14.3 months for placebo (HR = 0.78; P = .029). [15]Sorafenib was subsequently used as the 
control arm for the AXIS trial. 
In the AXIS trial, a randomised phase III trial, 723 patients with progression on first line 
Sunitinib, bevacizumab and IFN-α, temsirolimus or cytokines were randomised to receive 
either axitinib or sorafenib. Axitinib was shown to be superior to sorafenib in terms of PFS 
with axitinib having a median PFS of 6.7 months and sorafenib having a median PFS of 4.7 
months (HR 0·665; 95% CI 0·544-0·812; one-sided p<0·0001). There was no statistically 
significant difference in median OS between axitinib and sorafenib, 15.2 months versus 16.5 
months respectively (HR 0.997; CI 95 % 0.782–1.27). Subsequent lines of therapy may have 
contributed to this.[16] 
(2)Bii Recent additions to the market: Second line treatment  
Cabozantinib 
Cabozantinib is a tyrosine kinase inhibitor which targets VEGF, MET and AXL. The METEOR 
trial, a phase III randomised trial, randomised 658 patients who had progressed on first line 
VEGF targeted therapy to receive either cabozantinib or everolimus. Cabozantinib was 
associated with a statistically significant improvement in median OS as compared to 
everolimus, 21.4 months versus 16.5 months respectively (HR 0·66 [95% CI 0·53–0·83). 
Cabozantinib also resulted in improved median PFS compared to everolimus, 7.4 months 
versus 3.9 months (HR 0·51 [95% CI 0·41–0·62]; p<0·0001). 
More patients in the cabozantinib arm experienced grade 3 or grade 4 toxicity then in the 
everolimus arm 71% versus 60%. The most common grade 3 or above toxicities included 
hypertension (15%), Diarrhoea (13%), fatigue (11%) and palmar-plantar erythrodysaesthesia 
(8%). Dose reductions were required in 62% of patients receiving cabozantinib and 25% of 
patients receiving everolimus. Treatment was discontinued for adverse events excluding 
disease progression in 12% of patients treated with cabozantinib and 11% of patients 
treated with everolimus. There was a single report of a cabozantinib related death, the 
cause of death was not specified.[17] 
In April 2016 the FDA approved cabozantinib for patients who had received prior anti-
angiogenic therapy.  
In July 2016 the EMA granted market authorisation to cabozantinib for patients who 
progressed on prior VEGF targeted therapy. 
Nivolumab 
Nivolumab, an example of immune checkpoint blockade, is a fully humanised monoclonal 
antibody against programmed cell death 1 (PD-1). It acts to block the interaction between 
PD-1 and programmed cell death 1 ligands that occurs on the cell surface membrane thus 
blocking T cell inactivation by the cancer cell. In the Checkmate 025 study, a phase III 
randomised trial, 821 patients who had received one or two previous lines of anti 
angiogenic therapy were randomised in a 1:1 fashion to receive either Nivolumab or 
Everolimus. The primary end point of the study was OS. Checkmate 025 achieved its primary 
endpoint in that Nivolumab resulted in a statistically significant prolongation in median OS 
compared to everolimus, 25 months versus 19.6 months respectively 0.73 (98.5% CI, 0.57 to 
0.93; P=0.002). Interestingly despite achieving an OS benefit nivolumab failed to result in a 
statistically significant prolongation in PFS. Forty-four percent of patients in the nivolumab 
arm were treated beyond progression as they were defined as deriving clinical benefit.  
Nivolumab was associated with a median PFS of 4.6 months and everolimus a median PFS of 
4.4 months (HR 0.88; 95% CI, 0.75 to 1.03; P=0.11). The failure to achieve a PFS benefit was 
not explainable by cross over at progression, only 7 patients in the everolimus arm 
subsequently received anti PD-1 therapy. The results for OS and PFS were numerically 
similar to those observed in a non-randomised Phase II trial of nivolumab. The authors 
noted that for patients who had not died or experienced disease progression by 6 months a 
subset analysis demonstrated improved PFS for nivolumab compared with everolimus.  
Grade 3 or 4 toxicity occurred in 19% (n= 76) of patients who received nivolumab and 37% 
(n= 145) of patients who received everolimus. Grade 3 or 4 fatigue occurred in 2% of 
patients receiving nivolumab, the remainder of reported grade 3 or 4 toxicity occurred in ≤ 
1% of the patients receiving nivolumab. Dose delays were required in 51% of patients 
treated with nivolumab and 66% of those treated with everolimus. Treatment was 
discontinued for adverse events excluding disease progression in 8% of patients treated 
with nivolumab and 13% of patients treated with everolimus. Treatment with nivolumab 
resulted in a higher proportion of patients (55%) experiencing an improved quality of life as 
compared to everolimus (37%). [18] 
In November 2015 the FDA approved Nivolumab in mRCC in patients who had received prior 
anti-angiogenic treatment. 
In February 2016 the EMA’s Committee for Medicinal Products for Human Use (CHMP) 
recommended nivolumab be approved for use in patients who had progressed on prior anti-
angiogenic treatment, it is currently awaiting market authorisation. 
(2)C Combination therapy 
The combination of lenvatinib and everolimus has been proceeded by numerous attempts 
to combine VEGF targeted therapies and mTOR inhibitors in the clinical trial setting. Vertical 
blockade of the VEGF pathway is an attractive prospect in the treatment of RCC when we 
consider that a number of mechanisms by which RCC develops resistance to TKIs are 
mediated my activation of the HIF pathway. 
In a number of phase I/II trials, tyrosine kinase inhibitors such as sunitinib, sorafenib and 
pazopanib resulted in an unacceptable level of toxicity when combined with mTOR 
inhibitors such as everolimus and temsirolimus.[19-26] (TABLE 1) 
The combination of bevacizumab and a mTOR inhibitor was shown to be tolerable in the 
phase I/II setting. [27-29]Subsequent randomised trials did not demonstrate sufficient 
efficacy to warrant further development of the combination. 
The TORAVA trial, a French randomised phase II trial, randomised 171 patients with 
untreated mRCC across 3 arms: bevacizumab and temsirolimus, sunitinib, bevacizumab and 
interferon. Median PFS was 8.2 months (95% CI 7.0-9.6) for bevacizumab and temsirolimus, 
8.2 months (95% CI 5.5-11.7) for sunitinib and 16.8 (6.0-26.0) for interferon and 
bevacizumab. Notably, the combination of bevacizumab and temsirolimus resulted in more 
toxicity then expected with 77% of patients experiencing grade 3 or above toxicity and 44% 
of patients experiencing serious adverse events. [30] 
The INTORACT trial, a phase III randomised multicentre trial, compared the combination of 
Temsirolimus and bevacizumab with the combination of IFN-α and bevacizumab in 791 
patients in the first line setting. INTORACT did not result in a difference in PFS between the 
two treatment arms. Median progression free survival in the Temsirolimus-bevacizumab 
arm was 9.1 months and was not superior to the median PFS in the IFN-α and Bevacizumab 
arm of 9.3 months (HR 1.1; 95% CI, 0.9 to 1.3; P = .8). Median overall survival was similar in 
both the temsirolimus and bevacizumab arm (25.8 months) and the IFN-α and bevacizumab 
arm (25.5 months). [31] 
RECORD-2, a phase II randomised trial, randomised 365 patients with previously untreated 
mRCC to receive either everolimus in combination with bevacizumab or IFN-α in 
combination with bevacizumab. The was no statistically significant difference in median PFS 
between participants treated with everolimus-bevacizumab and those treated with IFN-α 
and bevacizumab, 9.3 months versus 10 months respectively (HR 0.91 95% CI 0.69-1.19, 
p=0.485). [32] 
The BEST trial, a randomised phase II trial, randomised 361 patients with mRCC to receive 
one of four regimens: single agent bevacizumab, Bevacizumab & Temsirolimus, 
bevacizumab & sorafenib or Temsirolimus & sorafenib. Patients could not have received 
prior anti angiogenic treatment but a single previous line of tumor vaccine or cytokine based 
immunotherapy was permitted. There was no statistically significant difference in median 
PFS between bevacizumab monotherapy (7.5 months) and any of the combination arms: 
bevacizumab & temsirolimus (7.6 months (HR 1.01, 95% CI 0.77-1.33, p=0.95)), bevacizumab 
and sorafenib (9.2 months (HR 0.89, 95% CI 0.68- 1.17, p=0.49)) temsirolimus and sorafenib 
(7.4 months (HR 1.07, 95% CI 0.82-1.41, p=0.68)). [33] 
Subsequent generations of tyrosine kinase inhibitors, such as dovitinib [34], vatalanib[35] 
and tizovanib[36], were subsequently combined with mTOR inhibitors. It was speculated 
that unique properties of these agents may result in more tolerable combinations with 
clinical activity. 
Dovitinib is a tyrosine kinase inhibitor that has activity in inhibiting VEGF but also fibroblast 
growth factor 2 (FGF-2). Fibroblast growth factor has been recognised as a possible target 
for overcoming resistance to VEGF targeted therapy. The combination of dovitinib and 
everolimus was examined in a Phase 1b trial of patients who had failed previous VEGF 
targeted therapy. Eighteen patients were enrolled. The MTD was dovitinib 200mg day 1-5 
every 7 days and everolimus 5mg od. In total 15 people received the MTD. Two patients had 
a PR, 3 patients had PD as their best response, the remainder had stable disease. Median 
PFS was 7 months (95% CI 2.3–10 months). There was no unexpected toxicity however there 
was a high rate of toxicity. Overall the authors concluded that the combination had 
demonstrated activity but further development was limited due to the toxicity profile of the 
combination.[34] 
Tivozanib was combined with temsirolimus in a phase 1b trial. Tivozanib targets VEGF 
receptor 1, VEGF receptor 2 and VEGF receptor 3. Tivozanib is known to be potent and 
selective. It was speculated that Tivozanib’s kinase selectivity would result in less off target 
side effects and thus produce a tolerable combination. In total 27 patients were treated, 20 
had received previous VEGF targeted therapy. No dose limiting toxicities were recorded thus 
the recommended phase 2 dose was temsirolimus 25mg weekly and Tivozanib 1.5 mg OD. 
Twenty-two patients were evaluated for response. Five patients achieved a PR and 15 
patients achieved stable disease. All five patients who achieved a PR had received prior 
VEGF targeted therapy and 66% of those who achieved stable disease had previously 
received VEGF targeted therapy. The median duration of stable disease was 9.2 months. The 
results of this trial were promising in that both agents were combined in therapeutic doses. 
The combination was tolerable and had signals of possible clinical efficacy. [36] The 
combination of Tivozanib and everolimus warrants further investigation. 
Overall numerous trials have attempted to successfully combine VEGF targeted therapy and 
mTOR targeted therapy. Efforts at combining therapies at therapeutic doses have been 
limited by toxicity. Agents which are potent and have high kinase selectivity, which result in 
less off target side effects, have the greatest potential for successful combination treatment 
in future clinical trials. 
 (3) Introduction to lenvatinib 
(3)A  Rationale for combination lenvatinib and everolimus in Renal cell cancer 
Lenvatinib is a multi targeted tyrosine kinase inhibitor. In a number of preclinical studies 
lenvatinib has demonstrated activity in targeting pathways central to RCC neo-angiogenesis, 
invasion and metastases. [37] 
A preclinical study involving a human breast cancer model lenvatinib was shown to be a 
potent inhibitor of VEGFR 3 kinase activity and VEGF- receptor 2 kinase activity. It also 
demonstrated inhibition of VEGFR-1, FGFR-1 and PDGFR β kinase. These receptors are active 
in angiogenesis and lymphangiogeneis. Dysregulation of pathways involving these receptors 
in malignancy promote tumor growth, invasion and metastases. [38] 
Lenvatinib demonstrated activity in the KIT signaling pathway in a human small cell lung 
cancer model. Lenvatinib inhibited stem cell factor induced angiogenesis.[39] 
Lenvatinib has demonstrated antitumor activity in RET gene fusion-driven preclinical cancer 
models.[40] RET expression has been noted in papillary RCC (up to 52% of patients in one 
study) but does not occur in clear cell RCC. The actual relevance RET expression has in 
papillary RCC can has yet to be determined. [41] 
Everolimus inhibits mTOR a downstream effector of the PI3K/AKT/mTOR pathway which 
controls cell proliferation and survival. mTOR inhibitors are also known to have an 
immunomodulatory effect. [42, 43]  
The combination of everolimus and lenvatinib targets multiple targets within two keys 
pathways in RCC tumorigenesis and metastases.  
 (3)B Chemistry 
The molecular formula of lenvatinib is C22H23ClN4O7S. 
The chemical formula of lenvatinib is 4-[3-chloro-4-(N′-cyclopropylureido)phenoxy]-7-
methoxyquinoline- 6-carboxamide.  
Lenvatinib has a unique binding mode with VEGFR2. Currently all approved TKI’s can be 
classed as type 1 or type 2 inhibitors based on the conformational state of the VEGFR2 they 
interact with. VEGFR2 in the active state (DFG-in) forms complexes with type 1 inhibitors 
whereas VEGFR2 in the inactive state (DFG-out) forms complexes with type 2 inhibitors. 
Lenvatinib’s binding mode isn’t consistent with either type 1 or type 2 inhibitors and instead 
occupies a new distinct class of type V inhibitors. Lenvatinib binds VEGFR2 in its DFG-in 
status. It can bind to both the ATP binding sit and the allosteric region of VEGFR2, a 
characteristic that is most often related to Type 2 (DFG-out) inhibitors. These features result 
in lenvatinib having a prolonged residence time as compared to type 1 inhibitors but also 
maintaining the characteristic of kinase selectivity. The clinical implications of lenvatinib’s 
status as a type V inhibitor have yet to be revealed but these unique characteristics may 
contribute to lenvatinib’s potency and side effect profile as seen in clinical trials. [44] 
(3)C Pharmacokinetics 
In the phase I setting lenvatinib was rapidly absorbed with tmax (time to maximum 
concentration) occurring at 3 hours. Cmax (maximum concentration) rose accordingly with 
escalating dose. Following multiple doses, no accumulation was observed. Following a single 
dose of lenvatinib measurable concentrations of lenvatinib were detectable for up to 7 days. 
Following a twice daily dose measurable concentrations of lenvatinib were detectable for up 
to 14 days. Plasma half-life was 28 hours. Elimination occurred mainly in faeces (64%) but 
also via urine (25%). Administration of food did not affect Cmax but did prolong tmax which 
was 2 hours in the fasting group and 5 hours in the fed group. [45, 46] 
In a phase II randomised trial Motzer et al observed that the pharmacokinetics of lenvatinib 
were best characterised as a three compartment model. Volume of distribution from the 
central compartment was 51.8 L and elimination occurred from this compartment. Volume 
of distribution in the two peripheral compartments was 31.2L and 43.6 L respectively. 
Clearance occurred at a rate of 7.4L/hour. Following oral administration of lenvatinib 
absorption was characterised as simultaneous first order absorption with a rate constant of 
1.08/hour, a zero order absorption duration of 0.83 hours and a lag time of 0.17 hours. The 
observed pharmacokinetic parameters of lenvatinib were not affected by creatinine 
clearance or everolimus administration. [47] 
In a phase 1 study in healthy patients the exposure of lenvatinib was shown to be slightly 
(15-19%) increased by co-administration with ketoconazole. [48] 
In a three way cross over study in healthy individuals lenvatinib was not shown to cause a 
clinically significant prolongation in QTc interval.[49] 
(4) Clinically efficacy 
(4)A Phase I data Lenvatinib  
In a phase 1 dose escalation study Boss et al examined the pharmacokinetics and safety of 
lenvatinib in 82 patients across multiple tumor types. Lenvatinib was administered once 
daily in a 28-day cycle with dose cohorts ranging from 0.2mg to 32mg. Maximum tolerated 
dose was defined as the highest dose at which one or less patients in a 6 patient cohort 
experiences a dose limiting toxicity. Maximum tolerated dose was reached at 25mg. At 
32mg dose limiting toxicity in the form of grade 3 proteinuria occurred in 2 patients. 
Of the 8 patients with RCC who received lenvatinib 4 experienced a partial response.  
Progression free survival for patients with RCC was 477 days (95% CI 279.0–559.0 days). [45] 
(4)B Phase I data Lenvatinib & Everolimus 
In a phase 1b study Molina et al examined the safety and maximum tolerated dose of 
lenvatinib combined with everolimus in 20 patients with advanced unresectable or 
metastatic RCC. Lenvatinib was administered at escalating doses to sequential cohorts of 
patients. Lenvatinib was administered at 12mg, 18mg and 24mg in combination with 
everolimus 5mg.Maximum tolerated dose was identified as 18mg lenvatinib. Dose limiting 
toxicity at the 24mg dose included nausea and vomiting and mucosal inflammation. 
Seventeen patients were evaluable for tumor response, no complete responses were 
observed, 6 patients experienced a partial response and 10 patients experienced stable 
disease. This translated into a disease control rate (DCR) of 80% across all 3 cohorts and a 
DCR of 83.3% for patients in the maximum tolerated dose (MTD) and low dose cohorts 
(n=18). In the MTD and low dose cohort PFS was 330 days (95 % CI 157–446; approximately 
10.9 months), PFS rate at 6 months was 72.1 % (95 % CI 48.8–95.4 % and PFS rate at 12 
months was 49.5 % (95 % CI 22.7–76.2 %). [50] 
(4)C Phase II data Lenvatinib & Everolimus 
In a phase II randomised, multi-center international trial Motzer et al randomised 153 
patients in a 1:1:1 fashion to receive either single agent lenvatinib (n=52), single agent 
everolimus (n=50) or lenvatinib and everolimus in combination (n=51).   
All participants had progressed on a single previous line of VEGF targeted therapy. 
Participants had not received prior treatment with a PD-1 inhibitor or an mTOR inhibitor. All 
participants included in final analysis had metastatic disease. 
The combination of lenvatinib and everolimus demonstrated a statistically significant 
prolongation of median PFS, the primary outcome of the study, compared to single agent 
everolimus, 14.6 (5·9–20·1) months versus 5.5 (3·5–7·1) months respectively (HR 0·40, 95% 
CI 0·24–0·68; p=0·0005). The combination arm had a numerically longer median PFS 
compared to the lenvatinib single agent arm 14.6 months versus 7.4 (5·6–10·2) months 
respectively, but this did not reach statistical significance (HR 0·66, 0·39–1·10; p=0·12). 
Comparison of median PFS in the two single agent arms favoured lenvatinib over everolimus 
(HR 0·61, 95% CI 0·38–0·98; p=0·048).  
The combination of lenvatinib and everolimus achieved an objective response in 22 patients 
(43%), a single patient achieved a CR and 21 patients achieved a PR. This was superior to the 
single agent everolimus arm in which 3 patients (6%) achieved a PR [RR] 7·2, 95% CI 2·3–
22·5; p<0·0001). The combination demonstrated a numerically superior objective response 
rate compared to single agent lenvatinib,43% versus 27% respectively, but this was not 
statistically significant (RR 1·6, 95% CI 0·9–2·8; p=0·10). Single agent lenvatinib was 
associated with a statistically significant improvement in objective response compared to 
single agent everolimus (RR 4·5, 95% CI 1·4–14·7; p=0·0067). 
Median duration of response was 13 months in the lenvatinib and everolimus combination 
arm and was prolonged in comparison to both single agent everolimus (8.5 months) and 
single agent lenvatinib (7.5 months).  
Median overall survival for the lenvatinib and everolimus combination arm was 25.5 months 
at primary data cut off in June 2014. This was numerically superior compared to single agent 
everolimus and single agent lenvatinib with median overall survivals of 18.4 months and 
17.5 months respectively. This did not reach statistical significance (combination versus 
everolimus HR 0·55, 95% CI 0·30–1·01; p=0·062, combination versus lenvatinib HR 0·74, 95% 
CI 0·40–1·36; p=0·30). A post hoc updated analysis was performed in December 2014. At 
this time the numerical difference in median OS between lenvatinib and everolimus and 
single agent everolimus had reached statistical significance 25.5months versus 15.4 months 
respectively (HR 0·51, 95% CI 0·30–0·88; p=0·024). In this post hoc analysis there continued 
to be no statistically significant improvement in median OS with lenvatinib and everolimus 
compared to single agent lenvatinib, 25.5 months versus 19.5 months respectively (HR 0·75, 
0·43–1·30; p=0·32). [47] 
An ad hoc retrospective blinded independent radiological review (IRR) was performed to see 
if investigator assessments, and survival data based on these, were reproducible by IRR. 
Eighty-six events were assessed by IRR; 101 events were included in the original analysis. 
PFS in the combination arm was significantly prolonged compared to the everolimus arm 
12.8 months versus 5.6 months respectively (HR 0·45 [95% CI 0·27–0·79]; p=0·0029). Single 
agent lenvatinib was associated with a numerically longer PFS compared to everolimus, 9 
months versus 5.6 months, but this did not reach statistical significance (HR 0·62 [95% CI 
0·37–1·04]; p=0·12). IRR assessed ORR was similar to investigator assessments. In the 
combination arm 17 patients experienced a partial response and a single patient achieved a 
complete response. In the lenvatinib single agent arm 19 patients experienced a partial 
response and one patient achieved a complete response. No patients in the everolimus arm 
experienced a complete or partial response.[51] 
(5) Safety and toxicity 
In a phase I study of single agent lenvatinib common treatment related adverse events 
included hypertension (40%), nausea (37%), diarrhoea (34%), stomatitis (32%), proteinuria 
(26%), vomiting (23%) and lethargy (23%). The most commonly documented non-
haematological grade 3 toxicities included hypertension (n=9, 11%) and proteinuria (n=6, 
7%). Six (7%) patients experienced haematological toxicity, 3 of these were grade 3 toxicities 
(thrombocytopenia n=1, neutropenia n=1, febrile neutropenia n=1) and there were 2 
reports of grade 4 thrombocytopenia.[45] 
In a phase Ib study of lenvatinib in combination with everolimus common treatment related 
adverse events included fatigue (60%), mucosal inflammation (50%), diarrhoea (40%), 
hypertension (40%), nausea and vomiting (40%) and proteinuria (40%). Toxicity was 
consistent with mTOR inhibition and VEGF inhibition. There were no new safety concerns 
identified. Grade 3 or 4 toxicity occurred in 75% (n=15) of participants and included 
hypertriglyceridemia (15%), proteinuria (15%), fatigue (10%)and diarrhoea (10%). A single 
death occurred secondary to cholangitis in the 12mg cohort. This was not felt to be related 
to lenvatinib or everolimus. [50] 
In a phase II randomised trial the most common grade 3 or 4 toxicities associated with single 
agent lenvatinib were diarrhoea (12%), hypertension (17%), proteinuria (19%), nausea (8%) 
and fatigue (8%). When lenvatinib was combined with everolimus common grade 3 or 4 
toxicities included diarrhoea (20%), fatigue (14%), hypertension (14%), vomiting (8%), 
hypertriglyceridemia (8%) and anaemia (8%). Patients receiving single agent everolimus 
experienced the fewest grade 3 or 4 adverse events, 50% compared to 79% of those 
receiving single agent lenvatinib and 71% of those receiving the combination. A single 
treatment related death occurred in the combination arm an intracranial bleed. A 
myocardial infarction resulting in death in the single agent lenvatinib group was classified as 
being possibly related to study drug. Dose reductions were necessary in 71% of patients 
receiving combination therapy and 62% of those receiving single agent lenvatinib. Toxicity 
requiring dose reduction occurred relatively early in treatment with 49% of patients 
receiving combination therapy and 38% of patients receiving single agent lenvatinib 
undergoing a dose reduction in the first 3 cycles. Toxicity was consistent with previous 
earlier phase trials and there were no new safety concerns raised. [47] 
(6) Regulatory Affairs 
In May 2016 the FDA approved the use of lenvatinib in combination with everolimus in 
patients with advanced RCC who have received one prior anti-angiogenic therapy. 
In July 2016 the EMA granted market authorisation to lenvatinib in combination with 
everolimus in patients with advanced RCC who had progressed on a previous line of VEGF 
targeted therapy. 
(7) Expert Commentary and Five-year review 
The recent additions of cabozantinib, nivolumab and combination everolimus-lenvatinib to 
the market will alter our current treatment algorithm for mRCC progressing on first line 
VEGF targeted therapy.  
Cabozantinib, nivolumab and combination lenvatinib and everolimus have all demonstrated 
improved efficacy over everolimus such that everolimus is no longer a reasonable agent to 
use for most patients in the second line setting. Everolimus will likely only be considered for 
second line treatment in patients where mTOR inhibition would be felt to be particularity 
viable or where there are specific concerns regarding toxicity of VEGF targeted therapy and 
immunotherapy.  
The place of axitinib in our treatment algorithm is less straight forward. No trials have 
examined the efficacy of cabozantinib, nivolumab or combination lenvatinib and everolimus 
compared to axitinib. Axitinib has never been directly compared to everolimus. Axitinib 
demonstrated improved PFS but not improved OS in the AXIS trial[52]. Axitinib is however a 
very active agent in a proportion of patients with a manageable toxicity profile such that, in 
our opinion, axitinib should continue to be included in the decision process for treating 
patients in the second line setting. 
 In the absence of head to head trials, decisions regarding the sequencing of available 
agents in the second line setting will be decided by the treating physician. Factors affecting 
this decision, on a case by case basis, could potentially include: efficacy, toxicity, cost, 
performance status and responses to previous therapy. 
Cabozantinib is associated with a predictable toxicity profile. Toxicity associated with 
combination lenvatinib and everolimus was similarly predictable. Nivolumab has been 
shown to be tolerable in multiple trials across multiple cancer types[53]. Our understanding 
of the long-term consequences of immunotherapy toxicity continues to evolve. Checkmate 
374, a phase 3b/4 safety trial of nivolumab in mRCC, will be crucial in informing our 
knowledge of the real-world profile of nivolumab NCT02596035. 
Nivolumab is an intravenous treatment with associated costs in terms of delivery of 
intravenous therapy.  Cabozantinib and combination everolimus-lenvatinib are oral 
treatments. The actual price of each agent will depend on the reimbursement that is 
established between the pharmaceutical company and the relevant regulatory authority in 
each country but given that lenvatinib and everolimus includes two agents this will likely 
result in increased expense.  
In terms of efficacy both Cabozantinib and Nivolumab have demonstrated improved OS 
compared to everolimus in a phase III trial. Lenvatinib in combination with everolimus has 
done so in a phase II setting. The OS results that reached statistical significance for 
combination lenvatinib and everolimus compared to everolimus were achieved in a post-
hoc analysis. It is also notable that a relatively small number of patients, 24 events in total, 
contributed to the OS calculation of combination lenvatinib and everolimus[47]. A 
confirmatory phase III trial would support the use of lenvatinib and everolimus in patients 
who have progressed on first line VEGF targeted therapy. A recent meta-analysis attempted 
to compare the OS associated with cabozantinib and nivolumab from two phase III trials 
using four Bayesian parametric survival network meta-analysis models. The authors noted 
that in the models utilising a time-varying HR cabozantinib was associated with improved OS 
in the first 5 months but following this nivolumab was associated with improved OS[54]. It is 
possible that this pattern reflects the maintained complete responses and maintained 
partial responses that are observed in a proportion of patients receiving immunotherapy. 
Maturing data from Checkmate 025 will better inform us regarding the rate of maintained 
CRs and PRs associated with nivolumab in mRCC. Given the current trend of rapid 
incorporation of immunotherapy into treatment algorithms, nivolumab will likely be a 
preferred second line agent among many physicians. 
Cabozantinib, nivolumab and combination everolimus and lenvatinib, are currently being 
examined in patients with mRCC in the first line setting. A phase II trial of cabozantinib 
compared to sunitinib in the first line setting was presented at ESMO 2016. Patients, 157 in 
total, with poor or intermediate risk mRCC were randomised to receive either cabozantinib 
or sunitinib. At median follow-up of 20.8 months cabozantinib was associated with a 
statistically significant prolongation in PFS, 8.2 months, compared to a PFS of 5.6 months in 
patients receiving sunitinib (adjusted HR 0.69, 95% CI 0.48-0.98, one-sided P = 0.012)[55]. A 
phase III randomised trial comparing Lenvatinib and everolimus, lenvatinib-pembrolizumab 
and sunitinib in the first line setting is currently recruiting NCT02811861. Checkmate 214, a 
randomised phase III trial, will compare combination ipilimumab and nivolumab to sunitinib 
in the first line setting NCT02231749. ADAPTeR, a phase II study, is currently examining the 
use of nivolumab prior to cytoreductive therapy NCT0244686. Several trials are examining 
the use of nivolumab in patients who do not have metastatic disease but have high risk 
renal cell cancer (NCT02595918, NCT02575222).  
The landscape of current trials for patients with mRCC who have progressed on prior VEGF 
targeted therapy shows a trend towards combining immunotherapy with either VEGF 
targeted therapy or novel compounds. Notable combinations currently in clinical trials 
include: avelumab and axitinib (NCT02684006), nivolumab and ibrutinib (NCT02899078) and 
pembrolizumab and bevacizumab (NCT02348008). 
It is undeniable that there has been a significant evolution in the agents we have available 
for the treatment of mRCC. We are still significantly limited in terms of biomarkers to help 
inform our decision process. In melanoma LDH has been shown to be a useful biomarker for 
response to PD-1 therapy[56], this has not yet been validated in renal cell cancer. The 
presence of CD3+ and CD8+ tumor infiltrating cells may have a role as a biomarker for 
response to PD-1 therapy[57]. In Checkmate 025 PD-L1 expression was not predictive of 
response to nivolumab. Reliable biomarkers that are reproducible in the clinical setting are 
urgently needed. 
Overall the therapeutic landscape of systemic therapy for RCC is currently evolving and 
guidelines and treatment paradigms will likely undergo significant change in the coming 
years. The positive signal for immunotherapy in RCC in Checkmate 025 will be a significant 
influence on how therapies develop in the coming years as will the positive signal for 
combination therapies. The agents that are currently approved in the second line setting 
may ultimately prove efficacious in the first line setting and the next generation of trials in 
the second line setting trend towards combining immunotherapy with VEGF targeting 
agents. Utilising our evolving arsenal of targeted therapies and immunotherapies to 
maximum effect will rely on the development of biomarkers and the recognition of 
mechanisms of resistance in tailoring sequential and combination therapy in the future. 
.  
(8) Key Points 
1. Current first line treatments for mRCC include sunitinib, pazopanib, and 
bevacizumab in combination with interferon. Temsirolimus has demonstrated 
efficacy in patients with negative prognostic factors. 
2. Historically second line therapies for mRCC have included everolimus and axitinib. 
Recent additions to the market will change our current treatment algorithm in the 
second line setting 
3. Cabozantinib and Nivolumab demonstrated an OS advantage compared to 
everolimus in phase III randomised trials. 
4. Combining VEGF targeted therapy and mTOR targeted therapy has been limited by 
significant toxicity.  
5. Lenvatinib and everolimus, in targeting two keys pathways in RCC tumorigenesis, is 
the first combination therapy that has been efficacious which still maintaining 
tolerability. 
6. Lenvatinib demonstrates unique pharmacodynamics properties which may 
contribute to the combinations success.  
7. The combination of Lenvatinib and everolimus has demonstrated a predictable and 
manageable toxicity profile. 
8. Lenvatinib enters the market at a time that two other agents have demonstrated 
activity in a similar setting in phase III randomised trials, cabozantinib and 
nivolumab. Each of these agents employs different strategies to improve upon 
previous targeted therapy.  
9. The therapeutic landscape of systemic therapy for RCC is currently evolving and 
guidelines and treatment paradigms will likely undergo significant change in the 
coming years.  
10. The positive signal for immunotherapy in RCC will be a significant influence on how 
therapies develop in the coming years as will the positive signal for combination 
therapies. 
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